# Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD

> **NCT04247594** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Voxelotor

## Key facts

- **NCT ID:** NCT04247594
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-09
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-06-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Data will not inform further development of Voxelotor
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04247594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04247594, "Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04247594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*